BOSTON, Mass., and SEATTLE, Wash., Jan. 10, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. Jak Knowles, M.D., Co-Founder, President and Chief Executive Officer, will present an overview of the company at 2:00 pm Eastern Time on Wednesday, January 12, 2022.
About Affini-T Therapeutics
Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering, and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T-cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.